Hydroxychloroquine as Prophylaxis for COVID-19: A Review.
Identifieur interne : 000630 ( Main/Corpus ); précédent : 000629; suivant : 000631Hydroxychloroquine as Prophylaxis for COVID-19: A Review.
Auteurs : Manuela Monti ; Bernadette Vertogen ; Carla Masini ; Caterina Donati ; Claudia Lilli ; Chiara Zingaretti ; Gerardo Musuraca ; Ugo De Giorgi ; Claudio Cerchione ; Alberto Farolfi ; Pietro Cortesi ; Pierluigi Viale ; Giovanni Martinelli ; Oriana NanniSource :
- Frontiers in pharmacology [ 1663-9812 ] ; 2020.
Abstract
The impact of the COVID-19 pandemic worldwide has led to a desperate search for effective drugs and vaccines. There are still no approved agents for disease prophylaxis. We thus decided to use a drug repositioning strategy to perform a state-of-the-art review of a promising but controversial drug, hydroxychloroquine (HCQ), in an effort to provide an objective, scientific and methodologically correct overview of its potential prophylactic role. The advantage of using known drugs is that their toxicity profile is well known and there are fewer commercial interests (e.g., expired patents), thus allowing the scientific community to be freer of constraints. The main disadvantage is that the economic resources are almost always insufficient to promote large multinational clinical trials. In the present study, we reviewed the literature and available data on the prophylactic use of HCQ. We also took an in-depth look at all the published clinical data on the drug and examined ongoing clinical trials (CTs) from the most important CT repositories to identify a supporting rationale for HCQ prophylactic use. Our search revealed a substantial amount of preclinical data but a lack of clinical data, highlighting the need to further assess the translational impact of in vitro data in a clinical setting. We identified 77 CTs using a multiplicity of HCQ schedules, which clearly indicates that we are still far from reaching a standard of care. The majority of the CTs (92%) are randomized and 53% are being conducted in a phase 3 or 2/3 setting. The comparator is placebo or control in 55 (77%) of the randomized studies. Forty-eight (62%) CTs expect to enroll up to 1,000 subjects and 50 (71%) plan to recruit healthcare workers (HCW). With regard to drug schedules, 45 (58.5%) CTs have planned a loading dose, while 18 (23.4%) have not; the loading dose is 800 mg in 19 trials (42.2%), 400 mg in 19 (42.2%), 600 mg in 4 (8.9%) and 1,200 mg in 1 (2.2%). Forty trials include at least one daily schedule, while 19 have at least one weekly schedule. Forty-one (53.2%) will have a treatment duration of more than 30 days. Awaiting further developments that can only derive from the results of these prospective randomized CTs, the take-home message of our review is that a correct methodological approach is the key to understanding whether prophylactic HCQ can really represent an effective strategy in preventing COVID-19.
DOI: 10.3389/fphar.2020.605185
PubMed: 33343376
PubMed Central: PMC7744418
Links to Exploration step
pubmed:33343376Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine as Prophylaxis for COVID-19: A Review.</title>
<author><name sortKey="Monti, Manuela" sort="Monti, Manuela" uniqKey="Monti M" first="Manuela" last="Monti">Manuela Monti</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vertogen, Bernadette" sort="Vertogen, Bernadette" uniqKey="Vertogen B" first="Bernadette" last="Vertogen">Bernadette Vertogen</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Masini, Carla" sort="Masini, Carla" uniqKey="Masini C" first="Carla" last="Masini">Carla Masini</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Donati, Caterina" sort="Donati, Caterina" uniqKey="Donati C" first="Caterina" last="Donati">Caterina Donati</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lilli, Claudia" sort="Lilli, Claudia" uniqKey="Lilli C" first="Claudia" last="Lilli">Claudia Lilli</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zingaretti, Chiara" sort="Zingaretti, Chiara" uniqKey="Zingaretti C" first="Chiara" last="Zingaretti">Chiara Zingaretti</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Musuraca, Gerardo" sort="Musuraca, Gerardo" uniqKey="Musuraca G" first="Gerardo" last="Musuraca">Gerardo Musuraca</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Giorgi, Ugo" sort="De Giorgi, Ugo" uniqKey="De Giorgi U" first="Ugo" last="De Giorgi">Ugo De Giorgi</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cerchione, Claudio" sort="Cerchione, Claudio" uniqKey="Cerchione C" first="Claudio" last="Cerchione">Claudio Cerchione</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Farolfi, Alberto" sort="Farolfi, Alberto" uniqKey="Farolfi A" first="Alberto" last="Farolfi">Alberto Farolfi</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cortesi, Pietro" sort="Cortesi, Pietro" uniqKey="Cortesi P" first="Pietro" last="Cortesi">Pietro Cortesi</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Viale, Pierluigi" sort="Viale, Pierluigi" uniqKey="Viale P" first="Pierluigi" last="Viale">Pierluigi Viale</name>
<affiliation><nlm:affiliation>Dipartimento di Scienze Mediche e Chirugiche, Università di Bologna, Bologna, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Martinelli, Giovanni" sort="Martinelli, Giovanni" uniqKey="Martinelli G" first="Giovanni" last="Martinelli">Giovanni Martinelli</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nanni, Oriana" sort="Nanni, Oriana" uniqKey="Nanni O" first="Oriana" last="Nanni">Oriana Nanni</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33343376</idno>
<idno type="pmid">33343376</idno>
<idno type="doi">10.3389/fphar.2020.605185</idno>
<idno type="pmc">PMC7744418</idno>
<idno type="wicri:Area/Main/Corpus">000630</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000630</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Hydroxychloroquine as Prophylaxis for COVID-19: A Review.</title>
<author><name sortKey="Monti, Manuela" sort="Monti, Manuela" uniqKey="Monti M" first="Manuela" last="Monti">Manuela Monti</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vertogen, Bernadette" sort="Vertogen, Bernadette" uniqKey="Vertogen B" first="Bernadette" last="Vertogen">Bernadette Vertogen</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Masini, Carla" sort="Masini, Carla" uniqKey="Masini C" first="Carla" last="Masini">Carla Masini</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Donati, Caterina" sort="Donati, Caterina" uniqKey="Donati C" first="Caterina" last="Donati">Caterina Donati</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lilli, Claudia" sort="Lilli, Claudia" uniqKey="Lilli C" first="Claudia" last="Lilli">Claudia Lilli</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zingaretti, Chiara" sort="Zingaretti, Chiara" uniqKey="Zingaretti C" first="Chiara" last="Zingaretti">Chiara Zingaretti</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Musuraca, Gerardo" sort="Musuraca, Gerardo" uniqKey="Musuraca G" first="Gerardo" last="Musuraca">Gerardo Musuraca</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De Giorgi, Ugo" sort="De Giorgi, Ugo" uniqKey="De Giorgi U" first="Ugo" last="De Giorgi">Ugo De Giorgi</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cerchione, Claudio" sort="Cerchione, Claudio" uniqKey="Cerchione C" first="Claudio" last="Cerchione">Claudio Cerchione</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Farolfi, Alberto" sort="Farolfi, Alberto" uniqKey="Farolfi A" first="Alberto" last="Farolfi">Alberto Farolfi</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cortesi, Pietro" sort="Cortesi, Pietro" uniqKey="Cortesi P" first="Pietro" last="Cortesi">Pietro Cortesi</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Viale, Pierluigi" sort="Viale, Pierluigi" uniqKey="Viale P" first="Pierluigi" last="Viale">Pierluigi Viale</name>
<affiliation><nlm:affiliation>Dipartimento di Scienze Mediche e Chirugiche, Università di Bologna, Bologna, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Martinelli, Giovanni" sort="Martinelli, Giovanni" uniqKey="Martinelli G" first="Giovanni" last="Martinelli">Giovanni Martinelli</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nanni, Oriana" sort="Nanni, Oriana" uniqKey="Nanni O" first="Oriana" last="Nanni">Oriana Nanni</name>
<affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Frontiers in pharmacology</title>
<idno type="ISSN">1663-9812</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The impact of the COVID-19 pandemic worldwide has led to a desperate search for effective drugs and vaccines. There are still no approved agents for disease prophylaxis. We thus decided to use a drug repositioning strategy to perform a state-of-the-art review of a promising but controversial drug, hydroxychloroquine (HCQ), in an effort to provide an objective, scientific and methodologically correct overview of its potential prophylactic role. The advantage of using known drugs is that their toxicity profile is well known and there are fewer commercial interests (e.g., expired patents), thus allowing the scientific community to be freer of constraints. The main disadvantage is that the economic resources are almost always insufficient to promote large multinational clinical trials. In the present study, we reviewed the literature and available data on the prophylactic use of HCQ. We also took an in-depth look at all the published clinical data on the drug and examined ongoing clinical trials (CTs) from the most important CT repositories to identify a supporting rationale for HCQ prophylactic use. Our search revealed a substantial amount of preclinical data but a lack of clinical data, highlighting the need to further assess the translational impact of <i>in vitro</i>
data in a clinical setting. We identified 77 CTs using a multiplicity of HCQ schedules, which clearly indicates that we are still far from reaching a standard of care. The majority of the CTs (92%) are randomized and 53% are being conducted in a phase 3 or 2/3 setting. The comparator is placebo or control in 55 (77%) of the randomized studies. Forty-eight (62%) CTs expect to enroll up to 1,000 subjects and 50 (71%) plan to recruit healthcare workers (HCW). With regard to drug schedules, 45 (58.5%) CTs have planned a loading dose, while 18 (23.4%) have not; the loading dose is 800 mg in 19 trials (42.2%), 400 mg in 19 (42.2%), 600 mg in 4 (8.9%) and 1,200 mg in 1 (2.2%). Forty trials include at least one daily schedule, while 19 have at least one weekly schedule. Forty-one (53.2%) will have a treatment duration of more than 30 days. Awaiting further developments that can only derive from the results of these prospective randomized CTs, the take-home message of our review is that a correct methodological approach is the key to understanding whether prophylactic HCQ can really represent an effective strategy in preventing COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33343376</PMID>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>22</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN>
<JournalIssue CitedMedium="Print"><Volume>11</Volume>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>Frontiers in pharmacology</Title>
<ISOAbbreviation>Front Pharmacol</ISOAbbreviation>
</Journal>
<ArticleTitle>Hydroxychloroquine as Prophylaxis for COVID-19: A Review.</ArticleTitle>
<Pagination><MedlinePgn>605185</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2020.605185</ELocationID>
<Abstract><AbstractText>The impact of the COVID-19 pandemic worldwide has led to a desperate search for effective drugs and vaccines. There are still no approved agents for disease prophylaxis. We thus decided to use a drug repositioning strategy to perform a state-of-the-art review of a promising but controversial drug, hydroxychloroquine (HCQ), in an effort to provide an objective, scientific and methodologically correct overview of its potential prophylactic role. The advantage of using known drugs is that their toxicity profile is well known and there are fewer commercial interests (e.g., expired patents), thus allowing the scientific community to be freer of constraints. The main disadvantage is that the economic resources are almost always insufficient to promote large multinational clinical trials. In the present study, we reviewed the literature and available data on the prophylactic use of HCQ. We also took an in-depth look at all the published clinical data on the drug and examined ongoing clinical trials (CTs) from the most important CT repositories to identify a supporting rationale for HCQ prophylactic use. Our search revealed a substantial amount of preclinical data but a lack of clinical data, highlighting the need to further assess the translational impact of <i>in vitro</i>
data in a clinical setting. We identified 77 CTs using a multiplicity of HCQ schedules, which clearly indicates that we are still far from reaching a standard of care. The majority of the CTs (92%) are randomized and 53% are being conducted in a phase 3 or 2/3 setting. The comparator is placebo or control in 55 (77%) of the randomized studies. Forty-eight (62%) CTs expect to enroll up to 1,000 subjects and 50 (71%) plan to recruit healthcare workers (HCW). With regard to drug schedules, 45 (58.5%) CTs have planned a loading dose, while 18 (23.4%) have not; the loading dose is 800 mg in 19 trials (42.2%), 400 mg in 19 (42.2%), 600 mg in 4 (8.9%) and 1,200 mg in 1 (2.2%). Forty trials include at least one daily schedule, while 19 have at least one weekly schedule. Forty-one (53.2%) will have a treatment duration of more than 30 days. Awaiting further developments that can only derive from the results of these prospective randomized CTs, the take-home message of our review is that a correct methodological approach is the key to understanding whether prophylactic HCQ can really represent an effective strategy in preventing COVID-19.</AbstractText>
<CopyrightInformation>Copyright © 2020 Monti, Vertogen, Masini, Donati, Lilli, Zingaretti, Musuraca, De Giorgi, Cerchione, Farolfi, Cortesi, Viale, Martinelli and Nanni.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monti</LastName>
<ForeName>Manuela</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vertogen</LastName>
<ForeName>Bernadette</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Masini</LastName>
<ForeName>Carla</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Donati</LastName>
<ForeName>Caterina</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lilli</LastName>
<ForeName>Claudia</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zingaretti</LastName>
<ForeName>Chiara</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Musuraca</LastName>
<ForeName>Gerardo</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>De Giorgi</LastName>
<ForeName>Ugo</ForeName>
<Initials>U</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cerchione</LastName>
<ForeName>Claudio</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Farolfi</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cortesi</LastName>
<ForeName>Pietro</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Viale</LastName>
<ForeName>Pierluigi</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Dipartimento di Scienze Mediche e Chirugiche, Università di Bologna, Bologna, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martinelli</LastName>
<ForeName>Giovanni</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nanni</LastName>
<ForeName>Oriana</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>12</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Front Pharmacol</MedlineTA>
<NlmUniqueID>101548923</NlmUniqueID>
<ISSNLinking>1663-9812</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">clinical trials</Keyword>
<Keyword MajorTopicYN="N">hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">prophylaxis</Keyword>
<Keyword MajorTopicYN="N">review</Keyword>
</KeywordList>
<CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>09</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>11</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>12</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>4</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>12</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>12</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33343376</ArticleId>
<ArticleId IdType="doi">10.3389/fphar.2020.605185</ArticleId>
<ArticleId IdType="pii">605185</ArticleId>
<ArticleId IdType="pmc">PMC7744418</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2020 Jun 16;172(12):819-821</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2020 Aug;108(2):253-263</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32285930</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Mar;55(3):105923</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32070753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacol Ther. 2020 Oct;108(4):766-769</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32344449</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Oct 17;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33068425</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2020 Sep 30;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33001138</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2020 Aug 26;11(1):4253</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32848158</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105932</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32145363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Rheum Dis. 2020 May;23(5):613-619</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32281213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Sep;585(7826):584-587</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32698191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):585-586</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32492298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>One Health. 2020 Dec;10:100141</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32562480</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000630 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000630 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:33343376 |texte= Hydroxychloroquine as Prophylaxis for COVID-19: A Review. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33343376" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |